VentriPoint Diagnostics Ltd. (CVE:VPT) Director George Adams sold 1,525,500 shares of the business’s stock in a transaction dated Friday, August 16th. The shares were sold at an average price of C$0.14, for a total value of C$213,570.00. Following the completion of the sale, the director now owns 43,724 shares in the company, valued at C$6,121.36.

VentriPoint Diagnostics stock traded down C$0.01 during midday trading on Thursday, reaching C$0.12. The stock had a trading volume of 106,500 shares, compared to its average volume of 186,570. VentriPoint Diagnostics Ltd. has a 12 month low of C$0.10 and a 12 month high of C$0.27. The firm’s 50-day moving average price is C$0.15 and its 200 day moving average price is C$0.15. The firm has a market capitalization of $7.57 million and a PE ratio of -2.16.

VentriPoint Diagnostics Company Profile

Ventripoint Diagnostics Ltd., a medical device company, develops and commercializes diagnostic tools that monitor patients with heart disease primarily in Canada, the Unites States, and China. The company offers Ventripoint Medical System, medical imaging system that is used to generate three-dimensional models with critical volume and functional measurements of a patient's heart chambers.

Featured Story: Call Option Volume

Receive News & Ratings for VentriPoint Diagnostics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for VentriPoint Diagnostics and related companies with's FREE daily email newsletter.